Cited by 466Glioma Diagnosis and TreatmentLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R., Kapadia, Ami, Malec, Mary, Berger, Mitchel S., Stokoe, David·2005·JNCI Journal of the National Cancer Institute

DOI 10.1093/jnci/dji161

Open this paper in CoChat — free account

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide. METHODS: Expression of EGFR and ligand-independent EGFRvIII mutant proteins and of phosphorylated protein kinase B (PKB)/Akt in specimens from glioma patients were assessed by immunohistochemistry. EGFR gene amplification was evaluated by fluorescence in situ hybridization. Mutations in PTEN and EGFR were assessed by polymerase chain reaction amplification and sequencing. Response was evaluated by sequential magnetic resonance imaging every 2 months. The Cochran-Mantel-Haenzel test was used to assess associations between biomarker status and response. All statistical tests were two-sided. RESULTS: Of 41 glioma patients, eight responded to treatment. Response to erlotinib was associated with EGFR expression (P = .07) and EGFR amplification (P = .08). These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively). Among six responders with sufficient tumor tissue, none had EGFRvIII mutations. None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001). The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001). CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

Integrity signals

Registry

Crossref · 10.1093/jnci/dji161

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695
EGFR and cancer prognosis.
Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548

Show all 37 references

Research works printed but not linked: 2

Salz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc ASCO2001 (abstr); 20 : 7A .
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO2002 (abstr); 21 : 504 .

Sorted by citations

Items 201–300 of 466

Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies
Thaker, N. G., & Pollack, I. F. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.116 · Cited by 40
Molecularly targeted therapies for malignant gliomas: advances and challenges
Peñas-Prado, M., & Gilbert, M. R. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.5.641 · Cited by 42
Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide
Lagarce, F., Messaoudi, K., Saulnier, P., Boesen, K., & Benoît, J. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s59134 · Cited by 49
Targeted molecular therapy of malignant gliomas
Kesari, S., Ramakrishna, N. R., Sauvageot, C., Stiles, C. D., & Wen, P. Y. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0011-y · Cited by 40
Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells
He, X., Liu, X.-J., Chen, X., Bian, L., Zhao, W., Shen, J.-K., & Sun, Q. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.099 · Cited by 40
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Gallego, O. S., Cuatrecasas, M., Benavides, M., Segura, P. P., Berrocal, A., Erill, N., Colomer, A., Quintana, M. J., Balañá, C., Gil, M., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1316-y · Cited by 40
Broad Phenotypic Changes Associated with Gain of Radiation Resistance in Head and Neck Squamous Cell Cancer
Bansal, N., Mims, J., Kuremsky, J. G., Olex, A. L., Zhao, W., Yin, L.-M., Wani, R., Qian, J. X., Marrs, G. S., Porosnicu, M., et al. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5690 · Cited by 40
Treatment options for recurrent glioblastoma: pitfalls and future trends
Franceschi, E., Tosoni, A., Bartolini, S., Mazzocchi, V., Fioravanti, A., & Brandes, A. A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.23 · Cited by 40
Predictive and Prognostic Markers in Neuro-Oncology
van den Bent, M. J., & Kros, J. M. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815c39f1 · Cited by 39
Second Messenger Systems in Human Gliomas
McLendon, R. E., Turner, K. C., Perkinson, K. R., & Rich, J. N. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1585-smsihg · Cited by 40
Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
Wen, P. Y., Kesari, S., & Drappatz, J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.733 · Cited by 40
Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas
Qaddoumi, I. A., Koçak, M., Panandiker, A. S. P., Armstrong, G. T., Wetmore, C., Crawford, J. R., Lin, T., Boyett, J. M., Kun, L. E., Boop, F. A., et al. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00067 · Cited by 40
In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation
Ranza, E., Mazzini, G., Facoetti, A., & Nano, R. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9975-4 · Cited by 39
Targeted Therapy in Gliomas
Hamza, M. A., & Gilbert, M. R. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0379-z · Cited by 39
Involvement of estrogen receptor β5 in the progression of glioma
Li, W., Winters, A., Poteet, E. C., Ryou, M., Lin, S., Hao, S., Wu, Z., Yuan, F., Hatanpaa, K. J., Simpkins, J. W., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.02.004 · Cited by 38
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System
Nieto‐Sampedro, M., Valle‐Argos, B., Gómez‐Nicola, D., Fernández‐Mayoralas, A., & Nieto‐Díaz, M. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7685 · Cited by 39
Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis
Chen, J.-R., Xu, H., Yao, Y., & Qin, Z.-Y. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12401 · Cited by 38
Multifaceted Dysregulation of the Epidermal Growth Factor Receptor Pathway in Clear Cell Sarcoma of the Kidney
Little, S. E., Bax, D. A., Rodriguez-Pinilla, M. S., Natrajan, R., Messahel, B., Pritchard‐Jones, K., Vujanic, G. M., Reis-Filho, J. S., & Jones, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0398 · Cited by 38
Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates
Simpson, L., & Galanis, E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.11.1593 · Cited by 38
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Kwatra, M. M. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009616666161227091522 · Cited by 37
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Siker, M., Chakravarti, A., & Mehta, M. P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.04.005 · Cited by 36
Anti-cancer Therapies in High Grade Gliomas
Tănase, C., Enciu, A., Mihai, S., Neagu, A. I., Calenic, B., & Cruceru, M. L. (2013) · Current Proteomics · doi:10.2174/1570164611310030007 · Cited by 36
Heme Oxygenase-1 and Carbon Monoxide Regulate Growth and Progression in Glioblastoma Cells
Castracani, C. C., Longhitano, L., Distefano, A., Rosa, M. D., Pittalà, V., Lupo, G., Caruso, M., Corona, D., Tibullo, D., & Volti, G. L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01869-7 · Cited by 35
Molecularly Targeted Therapies for Malignant Gliomas
Argyriou, A. A., & Kalofonos, H. P. (2009) · Molecular Medicine · doi:10.2119/molmed.2008.00123 · Cited by 34
Current and emerging molecular targets in glioma
Roesler, R., Brunetto, A. T., Abujamra, A. L., de Farias, C. B., Brunetto, A. L., & Schwartsmann, G. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.167 · Cited by 36
Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion
Nakada, M., Kita, D., Teng, L., Pyko, I. V., Watanabe, T., Hayashi, Y., & Hamada, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-30651-9_8 · Cited by 37
Will Kinase Inhibitors Make it as Glioblastoma Drugs?
Mellinghoff, I. K., Schultz, N. D., Mischel, P. S., & Cloughesy, T. F. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_178 · Cited by 36
Correlation Analysis between Single-Nucleotide Polymorphism and Expression Arrays in Gliomas Identifies Potentially Relevant Target Genes
Kotliarov, Y., Kotliarova, S. E., Charong, N., Li, A., Walling, J., Aquilanti, E., Ahn, S. J., Steed, M. E., Su, Q., Zenklusen, J. C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2496 · Cited by 34
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
Meany, H. J., Fox, E., McCully, C. L., Tucker, C., & Balis, F. M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0616-3 · Cited by 34
PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541
Hägerstrand, D., Lindh, M. B., Peña, C., Garcı́a-Echeverrı́a, C., Nistér, M., Hofmann, F., & Östman, A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq029 · Cited by 34
Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents
Tourneau, C. L., Vidal, L., & Siu, L. L. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.04.001 · Cited by 34
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
D’Alessandris, Q. G., Montano, N., Cenci, T., Martini, M., Lauretti, L., Bianchi, F., Larocca, L. M., Maira, G., Fernández, E., & Pallini, R. (2012) · Acta Neurochirurgica · doi:10.1007/s00701-012-1536-5 · Cited by 35
Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies
Argyriou, A. A., Antonacopoulou, A. G., Iconomou, G., & Kalofonos, H. P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.05.005 · Cited by 33
New prospects for management and treatment of inoperable and recurrent skull base meningiomas
Johnson, M. D., Sade, B., Milano, M. T., Lee, J. H., & Toms, S. A. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9434-z · Cited by 33
Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Narayan, R. S., Fedrigo, C. A., Stalpers, L. J. A., Baumert, B. G., & Sminia, P. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804547286 · Cited by 32
Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets
Persson, O., Krogh, M., Saal, L. H., Englund, E. M., Liu, J., Parsons, R. E., Mandahl, N., Borg, Å., Widegren, B., & Salford, L. G. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9383-6 · Cited by 32
Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance
Metro, G., Finocchiaro, G., & Cappuzzo, F. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj920 · Cited by 31
Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study
Wager, M., Meneï, P., Guilhot, J., Levillain, P., Michalak, S., Bataille, B., Blanc, J.-L., Lapierre, F., Rigoard, P., Milin, S., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604378 · Cited by 30
Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study
Preusser, M., Gelpí, E., Rottenfusser, A., Dieckmann, K. U., Widhalm, G., Dietrich, W., Bertalanffy, A., Prayer, D., Hainfellner, J. A., & Marosi, C. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9608-3 · Cited by 31
Molecularly targeted therapies for glioma
Yamanaka, R., & Saya, H. (2009) · Annals of Neurology · doi:10.1002/ana.21793 · Cited by 29
Therapeutic Advances in Malignant Glioma: Current Status and Future Prospects
Robins, H. I., Lassman, A. B., & Khuntia, D. (2009) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2009.08.015 · Cited by 29
EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts
Gadji, M., Tsanaclis, A. M. C., Fortin, D., Krcek, J. P., Torchia, M. G., Mai, S., Drouin, R., & Klonisch, T. C. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.010 · Cited by 29
Immunohistochemical Classification of Primary and Secondary Glioblastomas
Lee, K. S., Choe, G., Nam, K. H., Seo, A. N., Yun, S., Kim, K. J., Cho, H. J., & Park, S. (2013) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2013.47.6.541 · Cited by 29
Erlotinib: early clinical development in brain cancer
Addeo, R., Zappavigna, S., Parlato, C., & Caraglia, M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918950 · Cited by 30
Should Biomarkers Be Used to Design Personalized Medicine for the Treatment of Glioblastoma?
Weller, M., Wick, W., Hegi, M. E., Stupp, R., & Tabatabai, G. (2010) · Future Oncology · doi:10.2217/fon.10.113 · Cited by 27
Machine Learning Analytics of Resting-State Functional Connectivity Predicts Survival Outcomes of Glioblastoma Multiforme Patients
Lamichhane, B., Daniel, A. G. S., Lee, J. J., Marcus, D. S., Shimony, J. S., & Leuthardt, E. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.642241 · Cited by 30
Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives
Ronellenfitsch, M. W., Steinbach, J. P., & Wick, W. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0154-5 · Cited by 28
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report
Rogers, L. R., LoRusso, P. M., Nadler, P. I., Malik, G. M., Shields, A. F., & Kaelin, W. G. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0244-3 · Cited by 27
Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
Bartholomeusz, C., Yamasaki, F., Saso, H., Kurisu, K., Hortobágyi, G. N., & Ueno, N. T. (2011) · Journal of Cancer · doi:10.7150/jca.2.435 · Cited by 27
Strategies to Overcome Resistance to Targeted Protein Kinase Inhibitors in??the Treatment of Cancer
Buschbeck, M. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00002 · Cited by 27
Brain tumors: molecular biology and targeted therapies
Hegi, M. E., Murat, A., Lambiv, W. L., & Stupp, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl259 · Cited by 27
Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostaining
Hirano, H., Yonezawa, H., Yunoue, S., Habu, M., Uchida, H., Yoshioka, T., Kishida, S., Kishida, M., Oyoshi, T., Fujio, S., et al. (2013) · Brain Tumor Pathology · doi:10.1007/s10014-013-0153-1 · Cited by 26
Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response
Donoghue, J. F., Kerr, L., Alexander, N., Greenall, S. A., Longano, A., Gottardo, N. G., Wang, R., Tabar, V. S., Adams, T. E., Mischel, P. S., et al. (2018) · Cancers · doi:10.3390/cancers10080243 · Cited by 28
New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target?
Cloughesy, T. F., & Mischel, P. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2268 · Cited by 26
Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling
Hasselbalch, B., Lassen, U., Poulsen, H. S., & Stockhausen, M. (2010) · Cancer Investigation · doi:10.3109/07357907.2010.483506 · Cited by 27
Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma
Zhu, X., Pan, S., Li, R., Chen, Z., Xie, X., Han, D., Lv, S., & Huang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667884 · Cited by 24
Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β‐catenin
Wang, K., Park, J. O., & Zhang, M. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2693 · Cited by 24
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma (retracted)
Gatson, N. T., Weathers, S.-P. S., & de Groot, J. (2015) · CNS Oncology · doi:10.2217/cns.15.38 · Cited by 24
Retracted
Erlotinib‐Associated Acute Pneumonitis: Report of Two Cases
Vahid, B., & Esmaili, A. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/832605 · Cited by 24
A Pilot Study on EGFR-Targeted Molecular Imaging of PET/CT With 11C-PD153035 in Human Gliomas
Sun, J., Cai, L., Zhang, K., Zhang, A., Pu, P., Yang, W., & Gao, S. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182a23b73 · Cited by 24
Erlotinib in Gliomas: Should Selection Be Based on EGFR and Akt Analyses?
Cappuzzo, F. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji169 · Cited by 24
Molecular markers in gliomas: impact for the clinician
Höfer, S., & Lassman, A. B. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0157-2 · Cited by 23
Nimotuzumab in Pediatric Glioma
Lam, C. G., Bouffet, É., & Bartels, U. K. (2009) · Future Oncology · doi:10.2217/fon.09.119 · Cited by 23
Role of 17β-Estradiol on Cell Proliferation and Mitochondrial Fitness in Glioblastoma Cells
Castracani, C. C., Longhitano, L., Distefano, A., Anfuso, C. D., Kalampoka, S., Spina, E. L., Astuto, M., Avola, R., Caruso, M., Nicolosi, D., et al. (2020) · Journal of Oncology · doi:10.1155/2020/2314693 · Cited by 23
Chemotherapy in the treatment of malignant gliomas
Stern, J. I., & Raizer, J. J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.755 · Cited by 23
Cytotoxic Nitrobenzoyl Sesquiterpenoids from an Antarctica Sponge-Derived Aspergillus insulicola
Sun, C., Liu, X., Sun, N., Zhang, X., Shah, M., Zhang, G., Che, Q., Zhu, T., Li, J., & Li, D. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c01118 · Cited by 22
Update on Diagnostic Practice: Tumors of the Nervous System
Pytel, P., & Lukas, R. V. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.7.1062 · Cited by 22
Towards personalized therapy for patients with glioblastoma
Shirai, K., & Chakravarti, A. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.103 · Cited by 21
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays
Rubio‐Viqueira, B., Mezzadra, H., Nielsen, M. E., Jimeno, A., Zhang, X., Iacobuzio–Donahue, C. A., Maitra, A., Hidalgo, M. M., & Altiok, S. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0388 · Cited by 21
Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma
Wheeler, S., Egloff, A. M., Wang, L., James, C. D., Hammerman, P. S., & Grandis, J. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117781 · Cited by 22
Dacomitinib: an investigational drug for the treatment of glioblastoma
Sepúlveda-Sánchez, J. M., Sánchez‐Gómez, P., Salgado, M. Á. V., Gargini, R., & Balañá, C. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1528225 · Cited by 22
Novel Therapies for Malignant Gliomas
Cavaliere, R., Wen, P. Y., & Schiff, D. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.012 · Cited by 22
Predictive biomarkers investigated in glioblastoma
Tabouret, É., Chinot, O. L., Sanson, M., Loundou, A., Hoang‐Xuan, K., Delattre, J., & Idbaïh, A. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.945436 · Cited by 21
Anti‐tumour efficacy on glioma models of PHA ‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier
Albanese, C., Alzani, R., Amboldi, N., Degrassi, A., Festuccia, C., Fiorentini, F., Gravina, G. L., Mercurio, C., Pastori, W., Brasca, M. G., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12112 · Cited by 22
Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort
Quintela-Fandiño, M., Tourneau, C. L., Durán, I., Chen, E. X., Wang, L. E., Tsao, M., Bandarchi, B., Pham, N., Do, T., MacLean, M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0868 · Cited by 21
The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity
Boccellino, M., Quagliuolo, L., Alaia, C., Grimaldi, A., Addeo, R., Nicoletti, G. F., Kast, R. E., & Caraglia, M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1211522 · Cited by 21
Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas
Spinelli, G. P., Miele, E., Russo, G. L., Miscusi, M., Codacci-Pisanelli, G., Petrozza, V., Papa, A., Frati, L., Rocca, C. D., Gulino, A., et al. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912803251207 · Cited by 20
MAb 806 Enhances the Efficacy of Ionizing Radiation in Glioma Xenografts Expressing the de2-7 Epidermal Growth Factor Receptor
Johns, T. G., McKay, M. J., Cvrljevic, A. N., Gan, H. K., Taylor, C., Xu, H., Smyth, F. E., & Scott, A. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.027 · Cited by 20
Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology
Nutt, C. L. (2005) · Neurosurgical FOCUS · doi:10.3171/foc.2005.19.5.3 · Cited by 20
Identification of Glioblastoma Phosphotyrosine-Containing Proteins with Two-Dimensional Western Blotting and Tandem Mass Spectrometry
Guo, T., Wang, X., Li, M., Yang, H., Li, L., Peng, F., & Zhan, X. (2015) · BioMed Research International · doi:10.1155/2015/134050 · Cited by 19
The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro
Zhuang, H., Wang, J., Yuan, Z., Zhao, L., Wang, P., & Wang, C.-L. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-123 · Cited by 19
Pharmacotherapy for adults with tumors of the central nervous system
Schor, N. F. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.003 · Cited by 19
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Olin, M. R., Pluhar, G. E., Andersen, B. M., Shaver, R. L., Waldron, N. N., & Moertel, C. L. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014011577 · Cited by 18
Advances in malignant glioma drug discovery
Reardon, D. A., Perry, J., Brandes, A. A., Jalali, R., & Wick, W. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.584530 · Cited by 17
Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors
Tosi, U., Marnell, C. S., Chang, R. Y., Cho, W. C. S., Ting, R., Maachani, U. B., & Souweidane, M. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020351 · Cited by 18
Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the glioblastoma multiforme patients in the backdrop of mutational status of epidermal growth factor receptor and PTEN Genes
Arif, S. H., Pandith, A. A., Tabassum, R., Ramzan, A., Singh, S., Siddiqi, M. A., & Bhat, A. (2018) · Asian Journal of Neurosurgery · doi:10.4103/ajns.ajns_95_17 · Cited by 18
Signal transduction molecules in gliomas of all grades
Ermoian, R. P., Kaprealian, T. B., Lamborn, K. R., Yang, X., Jelluma, N., Arvold, N. D., Zeidman, R., Berger, M. S., Stokoe, D., & Haas-Kogan, D. A. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9683-5 · Cited by 17
Current concepts and newer developments in the treatment of malignant gliomas
Vogelbaum, M., & Omay, S. B. (2009) · Indian Journal of Cancer · doi:10.4103/0019-509x.49146 · Cited by 18
Emerging drugs for malignant glioma
Mason, W. P. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.1.81 · Cited by 18
Application of EGFR-TKIs in brain tumors, a breakthrough in future?
Feng, S., Liu, H., Yun, C., Zhu, W. Z., & Pan, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06448-9 · Cited by 19
Treatment of Glioblastoma in Elderly Patients: An Overview of Current Treatments and Future Perspective
Lanzetta, G., & Minniti, G. C. (2010) · Tumori Journal · doi:10.1177/030089161009600502 · Cited by 15
Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas
Yang, K., Ren, X., Tao, L., Wang, P., Jiang, H., Shen, L., Zhao, Y., Cui, Y., Li, M., & Lin, S. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.01.14 · Cited by 17
New chemotherapy options for the treatment of malignant gliomas
Soffietti, R., Rudà, R., & Trevisan, E. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801476fd · Cited by 17
Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib
McKibbin, T., Zhao, W. M., Tagen, M., Daw, N. C., Furman, W. L., McGregor, L. M., Geyer, J. R., Allen, J. W., & Stewart, C. F. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.007 · Cited by 17
Combination therapy for malignant glioma based on PTEN status
Gonzalez, J., & de Groot, J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.11.1767 · Cited by 17
Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines
Powe, E., Parschauer, D., Istifan, J., Lin, S., Duan, H., Gryka, R. J., Jean‐Louis, D., Tiwari, A. K., & Amos, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.952169 · Cited by 16
Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy
Tanaka, S., Luk, S. O., Kiyokawa, J., Onozato, M. L., Iafrate, A. J., Shah, K., Martuza, R. L., Rabkin, S. D., Batchelor, T. T., Cahill, D. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37437-2 · Cited by 15
Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87 MG glioblastoma cell proliferation induced by protein kinase inhibitors
Xing, W., Zou, Y., Han, Q., Dong, Y., Deng, Z., Lv, X., Jiang, T., & Ren, H. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12026 · Cited by 16
New developments in the treatment of malignant gliomas
Soffietti, R., Leoncini, B., & Rudà, R. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1313 · Cited by 16
Genetic signature of adult gliomas and correlation with MRI features
Bruzzone, M. G., Eoli, M., Cuccarini, V., Grisoli, M., Valletta, L., & Finocchiaro, G. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.44 · Cited by 16

Authors: Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., Berger, M. S., & Stokoe, D.
Affiliations: University of California, San Francisco (US)
Corresponding author: Haas-Kogan, Daphne A.
ORCID: Haas-Kogan, Daphne A.
Prados, Michael D.
Jelluma, Nannette
Arvold, Nils D.
Baumber, Rachel
Berger, Mitchel S.
Stokoe, David
Venue: JNCI Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2005-06-15
Volume: 97
Issue: 12
Pages: 880-887
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/dji161
OpenAlex: W2104743043
Cited by: 465
References: 37
Citations by year: 2026: 3 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 13 · 2016: 6 · 2015: 17 · 2014: 24 · 2013: 27 · 2012: 34
FWCI: 22.18
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5m01rr000079-42)
National Cancer Institute (P50CA097257)
National Institute of Neurological Disorders and Stroke (P01NS042927, P01 NS42927)
National Center for Research Resources (M01 RR-00079)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: erlotinib, EGFR tyrosine kinase inhibitors, high-grade glioma, glioblastoma, EGFR amplification, EGFRvIII, Akt phosphorylation, Akt, temozolomide, predictive biomarkers, treatment response, PTEN mutation, time to progression
MeSH terms: Erlotinib Hydrochloride, Temozolomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Drug Administration Schedule, Female, Glioma, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Supratentorial Neoplasms, Protein Serine-Threonine Kinases, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Area Under Curve, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks